RxDoctor Payments Data

Vidya Ajaradder, MD

Family Medicine · Greenville, SCNPI 1275543928

Payments from drug & device makers

$824in general payments, 2019–2025

Across 46 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$115
  • Boehringer Ingelheim$74
  • Lundbeck LLC$67
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66
  • Novo Nordisk$64
  • Dexcom, Inc.$63
  • plus $376 from 18 others

What the payments were for

  • Food & beverage$824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$824 in reported general payments places this provider in the 55th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$76,631
Medicare patients
153
Services billed
698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin94$116,931
OzempicSemaglutide99$91,845
JanuviaSitagliptin Phosphate38$38,981
EliquisApixaban34$30,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$30,546
MounjaroTirzepatide19$23,043
TrulicityDulaglutide20$22,195
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog22$16,037
Tresiba Flextouch U-100Insulin Degludec18$8,118
Albuterol Sulfate HfaAlbuterol Sulfate261$7,541
Lantus SolostarInsulin Glargine,hum.Rec.Anlog52$7,074
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$6,889
Breo ElliptaFluticasone/Vilanterol11$4,546
Novolog FlexpenInsulin Aspart20$3,468
SymbicortBudesonide/Formoterol Fumarate12$3,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$74$116,93194 claims
Novo NordiskOzempic$64$91,84599 claims
Lilly USA, LLCMounjaro, Trulicity$13$45,23839 claims
GSKTrelegy Ellipta, Breo Ellipta$15$35,09146 claims
PfizerEliquis$11$30,90234 claims
AstraZenecaSymbicort$13$3,32712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →